Tilbake til søkeresultatene

BIA-Brukerstyrt innovasjonsarena

Double sided silicon strip detection (DSSD) technology applied in cancer research

Tildelt: kr 5,2 mill.

Prosjektleder:

Prosjektnummer:

193210

Prosjektperiode:

2009 - 2011

Midlene er mottatt fra:

Organisasjon:

Geografi:

Fagområder:

Samarbeidsland:

The primary objective of this project is to achieve a Biomolex product for identifying the role of protein kinases in cancer diseases. This product will open up the market for Biomolex within the cancer research field. This will be done through developmen t of both software and tailored and generic protocols to be part of routines for: 1) Identifying kinases involved in or causing diseases 2)Modifying and modulating kinase activities by use of chemicals and compounds 3) Analyzing and monitoring the effect a specific treatment has on the overall kinase profile. This will identify and show the advantages of using DSSD technology to vastly improve the understanding of the mechanisms of molecular biology in cancer in order to achieve better diagnostic routin es and cancer treatments. The major R&D challenges relates to design of tailored Microphthalmia-Associated Transcription Factor (MITF) arrays, untangling of the importance of MITF splicing variants and establishment of detailed analysis pipelines. The protein kinase analysis market is of substantial size, involving both academia and pharmaceutical industry. More than 30% of all R&D spending in the pharmaceutical industry is focused on kinase analysis, especially in the areas of cancer, immune diseases and diabetes. The project will be run by Biomolex in collaborations with AstraZenca, Pepscan, Statistics for Innovation at Norsk Regnesentral, University of Leiden, and The Norwegian Radium Hospital. The project is unique on a worldwide scale, and repre sents a breakthrough in the necessary system improvements for protein kinase analysis in cancer research. Through developing the product based on the patented technology, we will be solving problems being a barrier towards shorten the drug development tim e and also reducing development costs related to cancer research.

Budsjettformål:

BIA-Brukerstyrt innovasjonsarena